Sodium salt 2-(3-hydroxy-pyridin-2-yl)-4-methyl-4,5-dihydro-thiazole-4-carboxylate

ID: ALA63540

Chembl Id: CHEMBL63540

PubChem CID: 135564781

Max Phase: Preclinical

Molecular Formula: C10H9N2NaO3S

Molecular Weight: 238.27

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Desferrithiocin

Canonical SMILES:  C[C@]1(C(=O)[O-])CSC(c2ncccc2O)=N1.[Na+]

Standard InChI:  InChI=1S/C10H10N2O3S.Na/c1-10(9(14)15)5-16-8(12-10)7-6(13)3-2-4-11-7;/h2-4,13H,5H2,1H3,(H,14,15);/q;+1/p-1/t10-;/m1./s1

Standard InChI Key:  UGJSEILLHZKUBG-HNCPQSOCSA-M

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 238.27

Molecular Weight (Monoisotopic): 238.0412

AlogP: 1.12

#Rotatable Bonds: 2

Polar Surface Area: 82.78

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 2.59

CX Basic pKa: 5.91

CX LogP: 0.32

CX LogD: -1.04

Aromatic Rings: 1

Heavy Atoms: 16

QED Weighted: 0.81

Np Likeness Score: 0.27

References

1. Bergeron RJ, Wiegand J, Dionis JB, Egli-Karmakka M, Frei J, Huxley-Tencer A, Peter HH..  (1991)  Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.,  34  (7): [PMID:2066978] [10.1021/jm00111a023]

2. Bergeron RJ, Wiegand J, Bharti N, McManis JS..  (2012)  Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.,  55  (16): [PMID:22889170] [10.1021/jm300509y]

Source

Source(1):

• Scientific Literature